on March 13, 2008
Published online before print March 13, 2008, doi: 10.1161/ATVBAHA.107.157776
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 14, 2007
Accepted on February 27, 2008
Suppression of the Raf/MEK/ERK Signaling Cascade and Inhibition of Angiogenesis by the Carboxyl Terminus of Angiopoietin-Like Protein 4
Ying-Hua Yang ;
From the Departments of Medicine (Y.-H.Y., K.S.L.L., M.-H.Y., K.K.Y.C., J.Z., W.Z., A.X.), Research Center of Heart, Brain, Hormone, and Healthy Aging (Y.-H.Y., Y.W., K.S.L.L., M.-H.Y., K.K.Y.C., J.Z., W.Z., A.X.), and Genome Research Center (Y.W.), and the Department of Pharmacology (A.X.), The University of Hong Kong, and the Guang Zhou Institute of Biomedicine and Health (D.W., A.X.), Chinese Academy of Sciences, China.
* To whom correspondence should be addressed. E-mail: amxu{at}hkucc.hku.hk.
Objectives—Angiopoietin-like protein 4 (Angptl4) is a secreted glycoprotein that has recently been implicated in the regulation of angiogenesis and metastasis. This study aimed to investigate the structural and cellular basis underlying the biological actions of Angptl4.
Methods and Results—Circulating Angptl4 was proteolytically cleaved into NH2-terminal coiled-coil domain (N-Angptl4) and COOH-terminal fibrinogen-like domain (C-Angptl4). Using amino acid sequencing analysis, we identified a major cleavage site between Lys168 and Leu169 and a minor cleavage site between Lys170 and Met171 in mouse Angptl4. C-Angptl4, but not N-Angptl4, potently inhibited both bFGF- and VEGF-induced cell proliferation, migration, and tubule formation in endothelial cells, and prevented neovascularization in mice. Treatment of C-Angptl4 with PNGase F (an N-glycosidase) ablated its N-linked glycosylation, and also significantly attenuated its antiangiogenic activities. C-Angptl4 blocked bFGF-induced activation of ERK1/2 MAP kinase, but had no obvious effect on Akt and P38 MAP kinase. Furthermore, C-Angptl4 abrogated bFGF-induced phosphorylation of Raf-1 and MEK1/2, whereas neither auto-phosphorylation of FGF receptor-1 nor activation of Ras was affected, suggesting that the blockage occurs at the level of Raf-1 activation.
Conclusions—The carboxyl terminus of Angptl4 alone is sufficient to suppress angiogenesis, possibly through inhibiting the Raf/MEK/ERK1/2 MAP kinase pathway in endothelial cells.
Key words: angiogenesis • angiopoietin-like proteins • glycosylation • MAP kinase • neovascularization
This article has been cited by other articles:
 |
|
 |
|
  S. K. Koliwad, T. Kuo, L. E. Shipp, N. E. Gray, F. Backhed, A. Y.-L. So, R. V. Farese Jr, and J.-C. Wang Angiopoietin-like 4 (ANGPTL4, Fasting-induced Adipose Factor) Is a Direct Glucocorticoid Receptor Target and Participates in Glucocorticoid-regulated Triglyceride Metabolism J. Biol. Chem., September 18, 2009; 284(38): 25593 - 25601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kersten, L. Lichtenstein, E. Steenbergen, K. Mudde, H. F.J. Hendriks, M. K. Hesselink, P. Schrauwen, and M. Muller Caloric Restriction and Exercise Increase Plasma ANGPTL4 Levels in Humans via Elevated Free Fatty Acids Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 969 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yin, S. Romeo, S. Chang, N. V. Grishin, H. H. Hobbs, and J. C. Cohen Genetic Variation in ANGPTL4 Provides Insights into Protein Processing and Function J. Biol. Chem., May 8, 2009; 284(19): 13213 - 13222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-h. Yau, Y. Wang, K. S. L. Lam, J. Zhang, D. Wu, and A. Xu A Highly Conserved Motif within the NH2-terminal Coiled-coil Domain of Angiopoietin-like Protein 4 Confers Its Inhibitory Effects on Lipoprotein Lipase by Disrupting the Enzyme Dimerization J. Biol. Chem., May 1, 2009; 284(18): 11942 - 11952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chomel, A. Cazes, C. Faye, M. Bignon, E. Gomez, C. Ardidie-Robouant, A. Barret, S. Ricard-Blum, L. Muller, S. Germain, et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity FASEB J, March 1, 2009; 23(3): 940 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. John-Aryankalayil, S. T. Palayoor, D. Cerna, M. T. Falduto, S. R. Magnuson, and C. N. Coleman NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells Mol. Cancer Ther., January 1, 2009; 8(1): 261 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Talmud, M. Smart, E. Presswood, J. A. Cooper, V. Nicaud, F. Drenos, J. Palmen, M. G. Marmot, S. M. Boekholdt, N. J. Wareham, et al. ANGPTL4 E40K and T266M: Effects on Plasma Triglyceride and HDL Levels, Postprandial Responses, and CHD Risk Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2319 - 2325. [Abstract] [Full Text] [PDF]
|
|